Leukemia

The Food and Drug Administration approved Nivestym (filgrastim-aafi), a biosimilar to Neupogen (filgrastim), for five eligible indications.

Today's approval of Tibsovo, along with the diagnostic tool to determine who should get it, brings a new type of treatment for patients with acute myeloid leukemia.

While there are known risk factors of developing acute myeloid leukemia (AML) – such as a myelodysplastic syndrome diagnosis and receiving chemotherapy and radiotherapy – a diagnosis can still stun and individual. But researchers at Weill Cornell Medicine and New York-Presbyterian recently discovered a genomic pre-malignant biomarker of the disease that can identify people who are at a greater risk for AML.

A national survey demonstrated shared feelings across all blood cancer types about treatment options and their side effects, as well as other social, financial and emotional aspects.

An Extraordinary Healer essay honoring KAITLYN WHITEWATER, B.S.N., RN [SAINT FRANCIS HOSPITAL, 7 WEST ONCOLOGY/BONE MARROW TRANSPLANT UNIT, TULSA, OKLAHOMA]

The Food and Drug Administration (FDA) has granted a priority review to a new drug application (NDA) for glasdegib to treat patients with previously untreated acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC), which is a type of chemotherapy, according to Pfizer, the manufacturer of the drug.

Nearly 20 percent of hematopoietic stem cell transplant (HSCT) survivors reported using cannabis, not just to ease physical and emotional side effects, but in the hopes that it would help treat their cancer, according to patient survey results presented at the 2018 of American Society of Clinical Oncology (ASCO) Annual Meeting.

The Food and Drug Administration (FDA) approved Venclexta (venetoclax) in combination with Rituxan (rituximab) for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without the genetic mutation 17p deletion, who have received at least one prior therapy.

Fueled by the tragic loss of their son, Tony and his wife Vicky Martell built the foundation by working closely with their passionate friends in the music industry to continue his legacy and expand the foundation’s fundraising initiatives every year.

The Food and Drug Administration (FDA) has granted a priority review to a new drug application (NDA) for gilteritinib for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia (AML), according to Astellas Pharma, the manufacturer of the FLT3 inhibitor.

The Leukemia & Lymphoma Society's (LLS) Clinical Trial Support Center helps patients with blood cancers find clinical trials that are right for them.

“A life is not important except in the impact it has on other lives.”

As suspected, the average early mortality rate improved overall during the study period. But while evaluating the data, researchers noticed something interesting about the difference in early mortality at the NCI-designated cancer centers compared to non-NCI-designated cancer centers.

Tavalisse (fostamatinib) was granted approval by the Food and Drug Administration (FDA) for patients with chronic immune thrombocytopenia (ITP) after they had an insufficiencent response to another therapy.

A new drug combination bested current standard of care in a clinical trial.

The Food and Drug Administration (FDA) granted duvelisib a priority review to a new drug application (NDA) for full approval to treat patients who have relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia (CLL/SLL). The FDA also granted an accelerated approval for the treatment of patients with relapsed or refractory follicular lymphoma.

After extensive chemo treatment was completed, intended to kill all the leukemic cells in my sick body, a courier was sent to Israel to collect the harvested marrow from my donor, and immediately fly it back to the U.S. where I was to be infused.

The potential approval offers hope to the rare blood cancer, which currently has no standard of care treatment protocol.

Blincyto (blinatumomab) was granted approval by the Food and Drug Administration (FDA) to treat patients who have B-cell precursor acute lymphoblastic leukemia (ALL), who are in remission but still have minimal residual disease (MRD).

Tasigna (nilotinib) was granted Food and Drug Administration (FDA) approval, to be used in the first- and second-line setting for pediatric patients 1 year old or older who have Philadelphia chromosome–positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP).

The time has finally come when researchers have found a way to harness the immune system and use it to fight blood cancers.

Never in their wildest dreams dreams would immunologists from the last generation have imagined chimeric antigen receptor (CAR)-T cell therapy coming to light. The very notion of genetically engineering a T cell to recognize a tumor antigen would have been viewed almost as a pipe dream.

Cognitive dysfunction among geriatric patients with blood cancers – such as multiple myeloma, leukemia and lymphoma – is not only prevalent, but may also impact long-term survival.

Survey finds quality of life and cost affect treatment decisions.